111 related articles for article (PubMed ID: 11391160)
1. Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches.
Lemiale F; Brand D; Lebigot S; Verrier B; Buzelay L; Brunet S; Barin F
J Acquir Immune Defic Syndr; 2001 Apr; 26(5):413-22. PubMed ID: 11391160
[TBL] [Abstract][Full Text] [Related]
2. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles.
Brand D; Lemiale F; Turbica I; Buzelay L; Brunet S; Barin F
AIDS Res Hum Retroviruses; 1998 Oct; 14(15):1369-77. PubMed ID: 9788678
[TBL] [Abstract][Full Text] [Related]
4. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
[TBL] [Abstract][Full Text] [Related]
5. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
6. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and immunogenic characterization of soluble human immunodeficiency virus type 1 envelope glycoprotein trimers expressed by semliki forest virus.
Forsell MN; Li Y; Sundbäck M; Svehla K; Liljeström P; Mascola JR; Wyatt R; Karlsson Hedestam GB
J Virol; 2005 Sep; 79(17):10902-14. PubMed ID: 16103142
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
9. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
Kothe DL; Decker JM; Li Y; Weng Z; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Salazar-Gonzalez JF; Moldoveanu Z; Mestecky J; Gao F; Haynes BF; Shaw GM; Muldoon M; Korber BT; Hahn BH
Virology; 2007 Mar; 360(1):218-34. PubMed ID: 17097711
[TBL] [Abstract][Full Text] [Related]
10. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
[TBL] [Abstract][Full Text] [Related]
11. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.
Chakrabarti BK; Ling X; Yang ZY; Montefiori DC; Panet A; Kong WP; Welcher B; Louder MK; Mascola JR; Nabel GJ
Vaccine; 2005 May; 23(26):3434-45. PubMed ID: 15837367
[TBL] [Abstract][Full Text] [Related]
12. Generation of HIV-1 potent and broad neutralizing antibodies by immunization with postfusion HR1/HR2 complex.
Dawood R; Benjelloun F; Pin JJ; Kone A; Chanut B; Jospin F; Lucht F; Verrier B; Moog C; Genin C; Paul S
AIDS; 2013 Mar; 27(5):717-30. PubMed ID: 23719346
[TBL] [Abstract][Full Text] [Related]
13. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
[TBL] [Abstract][Full Text] [Related]
14. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.
Verrier F; Burda S; Belshe R; Duliege AM; Excler JL; Klein M; Zolla-Pazner S
J Virol; 2000 Nov; 74(21):10025-33. PubMed ID: 11024131
[TBL] [Abstract][Full Text] [Related]
15. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
[TBL] [Abstract][Full Text] [Related]
16. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Semliki Forest virus based self-amplifying RNA expressing Indian HIV-1C genes in mice.
Ajbani SP; Velhal SM; Kadam RB; Patel VV; Bandivdekar AH
Int J Biol Macromol; 2015 Nov; 81():794-802. PubMed ID: 26361864
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140.
Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC
J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699
[TBL] [Abstract][Full Text] [Related]
19. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus.
Kahl CA; Marsh J; Fyffe J; Sanders DA; Cornetta K
J Virol; 2004 Feb; 78(3):1421-30. PubMed ID: 14722297
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
